Biosergen AB

OM:BIOSGN Stock Report

Market Cap: SEK 139.5m

Biosergen Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Tine Olesen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure2.3yrs

Recent management updates

Recent updates

CEO

Tine Olesen

less than a year

Tenure

Ms. Tine Kold Olesen, Ph D., serves as Chief Executive Officer of Biosergen AB since February 1, 2024. She served as Chief Operation Officer of Biosergen since March 2022 until February 1, 2024 and served...

Leadership Team

NamePositionTenureCompensationOwnership
Peder Andersen
Chief Medical Officerless than a yearSEK 1.62mno data
Tine Olesen
CEO & Member of Executive Boardless than a yearno datano data
Niels Laursen
Chief Financial Officer3.9yrsno datano data
Sergey Zotchev
Chief Scientific Officer and Member of Scientific Advisory Panelno datano datano data

1.0yrs

Average Tenure

Experienced Management: BIOSGN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sergey Zotchev
Chief Scientific Officer and Member of Scientific Advisory Panelno datano datano data
Anna Ljung
Chairpersonless than a yearno datano data
Mattias Klintemar
Board Member4yrsSEK 297.00kno data
Marianne Kock
Independent Deputy Chairperson4yrsSEK 290.00kno data
Robert Molander
Board Memberless than a yearno datano data

2.3yrs

Average Tenure

58yo

Average Age

Experienced Board: BIOSGN's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:07
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biosergen AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Herman KuntscherCarlsquare AB